近期,一款名为Re2O、俗称“尸皮针”的医美产品在轻医美市场走红。该产品的核心原料源自已故捐献者的人体皮肤组织,即人体脱细胞真皮细胞外基质 1。商家将其卖点标榜为“逆转肌肤衰老”,单针售价介于3000元至4000元人民币之间 1。然而,新京报评论指出,该产品仅在韩国和日本获批,未获得中国国家药监局注册认证,因此在国内流通及注射属于违规行为 1。
从医学安全性来看,现有的脱细胞技术无法完全清除细胞与遗传物质,这可能导致隐性遗传病或未知易感基因带来潜在的健康风险 1。此外,相关早期临床研究仅持续20周,样本量较小,缺乏大样本长周期的循证医学支持 1。今年10月,香港卫生署查获了一批此类网红医美产品,并强调其因缺乏临床安全数据而存在公共卫生风险 1。
除了安全风险,该领域还涉及医疗伦理与法律争议。将第三类医疗器械材料用于美容涉嫌技术滥用,且商家常隐瞒原材料来源,侵犯了消费者的知情权 1。消费者若选择赴韩注射,则面临跨国维权困难的现实问题 1。对此,评论呼吁监管部门应严查未经批准的国内非法销售、流通和注射行为,同时规范跨境医美营销,打击以“抗衰神针”等话术招揽消费者的虚假宣传及违法引流活动 1。
A recent commentary by Beijing News In-Depth has raised serious concerns about the growing popularity of a South Korean aesthetic injectable known colloquially as the “corpse skin needle,” or officially as Re2O. The product, which markets itself on the promise of “reversing skin aging” and allowing users to “return to age 20,” is derived from human skin tissue donated by deceased individuals. This material serves as an acellular dermal extracellular matrix, but the core ingredient’s origin from human cadavers has sparked significant ethical and safety debates 1. Priced between 3,000 and 4,000 yuan per injection, the treatment has gained traction in China’s light medical beauty market despite lacking approval from the National Medical Products Administration (NMPA) 1.
The primary risk associated with Re2O lies in the limitations of current decellularization technologies, which cannot guarantee the complete removal of cellular components and genetic material. Consequently, there remains a potential health risk regarding hidden genetic diseases or unknown susceptibility genes transferred through the tissue 1. Furthermore, the clinical evidence supporting the product’s long-term safety is weak; existing studies are based on small sample sizes and have only tracked patients for 20 weeks, failing to provide robust, large-scale empirical support 1. As a result, any domestic circulation or administration of this unregistered substance constitutes a violation of Chinese regulations 1.
Beyond scientific uncertainties, the commentary highlights legal and consumer rights issues. Vendors frequently obscure the source of their materials, thereby infringing upon consumers’ right to informed consent 1. Using Class III medical device materials purely for cosmetic purposes also raises questions about technological misuse 1. For those who travel to South Korea for these procedures, cross-border legal recourse presents considerable challenges should complications arise 1.
Regulatory bodies are beginning to take notice of these risks. In October of this year, Hong Kong’s Department of Health seized a batch of the “corpse skin needles” marketed online, emphasizing that the lack of clinical safety data poses public health hazards 1. In response to the trend, Beijing News In-Depth calls on authorities to strictly crack down on illegal sales, distribution, and injections within China. The publication also urges regulators to monitor cross-border marketing efforts, specifically targeting false advertising that uses terms like “miracle anti-aging needle” to lure consumers into potentially dangerous procedures 1.
评论
还没有评论,欢迎留下第一条。